1-(1,3-BENZODIOXOL-5-YL)-N-[5-[(S)-(2-CHLOROPHENYL)[(3R)-3-HYDROXY-1-PYRROLIDINYL]METHYL]-2-THIAZOLYL]-CYCLOPROPANECARBOXAMIDE structure
|
Common Name | 1-(1,3-BENZODIOXOL-5-YL)-N-[5-[(S)-(2-CHLOROPHENYL)[(3R)-3-HYDROXY-1-PYRROLIDINYL]METHYL]-2-THIAZOLYL]-CYCLOPROPANECARBOXAMIDE | ||
|---|---|---|---|---|
| CAS Number | 926664-32-6 | Molecular Weight | 497.99 | |
| Density | 1.510±0.06 g/cm3 (20 °C, 760 mmHg) | Boiling Point | N/A | |
| Molecular Formula | C25H24ClN3O4S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of 1-(1,3-BENZODIOXOL-5-YL)-N-[5-[(S)-(2-CHLOROPHENYL)[(3R)-3-HYDROXY-1-PYRROLIDINYL]METHYL]-2-THIAZOLYL]-CYCLOPROPANECARBOXAMIDEVRT-534 targets connexin 26 (Cx26). Vrt-534 exhibits dose-responsive binding to recombinant WT Cx26 and mutant Cx26 K188N with EC50 value of 19 μM and 5 μM, respectively. Vrt-534 can be used in research related to hearing impairment[1]. |
| Name | Cyclopropanecarboxamide, 1-(1,3-benzodioxol-5-yl)-N-[5-[(S)-(2-chlorophenyl)[(3R)-3-hydroxy-1-pyrrolidinyl]methyl]-2-thiazolyl] |
|---|
| Description | VRT-534 targets connexin 26 (Cx26). Vrt-534 exhibits dose-responsive binding to recombinant WT Cx26 and mutant Cx26 K188N with EC50 value of 19 μM and 5 μM, respectively. Vrt-534 can be used in research related to hearing impairment[1]. |
|---|---|
| Related Catalog | |
| Target |
Cx26:19 μM (EC50) |
| References |
| Density | 1.510±0.06 g/cm3 (20 °C, 760 mmHg) |
|---|---|
| Molecular Formula | C25H24ClN3O4S |
| Molecular Weight | 497.99 |
| Exact Mass | 497.11800 |
| PSA | 112.16000 |
| LogP | 4.36240 |